首页> 美国卫生研究院文献>Drug Safety - Case Reports >Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
【2h】

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report

机译:抗结核药物诱发的固定药物爆发:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox® (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox® for pulmonary tuberculosis. Tablet Forecox® was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization–Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox® was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug.
机译:固定药疹(FDE)是由片剂Forecox ®(利福平[rifampin] 225 mg +异烟肼150 mg +吡嗪酰胺750 mg +乙胺丁醇)的固定剂量联合用药(FDC)引起的一位患有药物过敏史的40岁男性患者中服用400毫克)。患者服用第三剂Forecox ®肺结核片剂后患上了FDE。 FDE治疗15天后撤回Tablet Forecox ®并使患者从反应中恢复。根据世界卫生组织-乌普萨拉监测中心(WHO-UMC)和Naranjo因果关系评估标准,反应和片剂Forecox ®之间的关联分别是可能的。根据改良的Hartwig和Siegel量表,反应为中度(4b级)严重。由于有药物过敏史的患者发生过敏反应的风险增加,因此不应使用FDC以避免鉴定罪魁祸首药物的复杂性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号